Compounding HRT Solutions for DHEA Optimization Patients

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, in the context of DHEA deficiency evaluation, low libido may present as a persistent reduction in spontaneous sexual desire, decreased frequency of sexual thoughts, and diminished responsiveness to intimacy cues. The guideline notes that declining androgen precursor levels — including DHEA — may be associated with reduced arousal, decreased lubrication, and loss of interest in initiating sexual activity, often alongside low mood and fatigue. Patients experiencing significant or sudden changes in sexual function should seek evaluation from a qualified clinician, as these symptoms may reflect underlying endocrine, psychological, or medical conditions requiring assessment.

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, fatigue associated with DHEA-related endocrine changes may present as persistent low energy that is not relieved by rest, reduced physical and cognitive stamina, and a general sense of exhaustion during routine activities. The guideline notes that declining adrenal hormone precursors may be associated with disruptions in energy regulation and stress response. Patients experiencing severe, progressive, or unexplained fatigue should seek evaluation from a qualified clinician, as fatigue may indicate a variety of endocrine or systemic conditions; sudden severe weakness, dizziness, or low blood pressure may require urgent medical attention.

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, depressed mood in the setting of DHEA deficiency evaluation may present as a persistent low mood with loss of interest or pleasure in usual activities, reduced energy and motivation, slowed thinking, poor concentration, irritability, tearfulness, and social withdrawal. The guideline notes that low DHEA and reduced adrenal steroid precursor availability may be associated with diminished stress resilience and mood dysregulation. Patients experiencing persistent or worsening depressed mood, feelings of hopelessness or worthlessness, or thoughts of self-harm should seek evaluation from a qualified clinician promptly, as these symptoms may reflect conditions requiring professional diagnosis and management.

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, decreased muscle mass associated with low DHEA may present as gradual loss of lean body mass, visible thinning of limbs, reduced muscle tone, and measurable declines in strength and endurance. According to the Endocrine Society Clinical Practice Guideline, declining androgen precursor levels may be associated with accelerated loss of lean muscle tissue and faster onset of fatigue during routine physical activity. According to NIH MedlinePlus, slower recovery after exertion may also accompany these changes. Patients experiencing significant or rapid muscle loss, difficulty performing daily activities, or unexplained weakness should seek evaluation from a qualified clinician, as these symptoms may indicate endocrine or nutritional conditions requiring professional assessment.

According to the FDA-approved prescribing information for DHEA (dehydroepiandrosterone), DHEA is an endogenous adrenal steroid precursor to androgens and estrogens. According to the FDA-approved prescribing information for DHEA and the Endocrine Society Clinical Practice Guideline, DHEA serves as a substrate for downstream sex hormone synthesis; the guideline notes that DHEA levels decline substantially with age and may be associated with changes in sexual function, bone density, mood, and body composition. Per the FDA-approved prescribing information for DHEA, therapy may be associated with androgenic effects including acne, hair changes, and irritability, and monitoring of hormone levels and symptoms is recommended. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing. Commercially available DHEA products are separately regulated, and clinical decisions about whether to use DHEA in any form belong with the prescribing clinician.

According to the FDA-approved prescribing information for Rosuvastatin, Rosuvastatin is a selective HMG-CoA reductase inhibitor indicated as adjunctive therapy to diet to reduce elevated LDL cholesterol, total cholesterol, triglycerides, and apolipoprotein B, and to increase HDL cholesterol in patients with primary hyperlipidemia or mixed dyslipidemia. According to the FDA-approved prescribing information for Rosuvastatin, its mechanism involves decreasing hepatic cholesterol synthesis and increasing LDL receptor activity, resulting in improved lipid parameters. Per the FDA-approved prescribing information for Rosuvastatin, it may be associated with myopathy and rhabdomyolysis; patients should be instructed to report unexplained muscle pain, tenderness, or weakness promptly. Liver enzyme abnormalities may occur; hepatic function monitoring is recommended. According to the American Diabetes Association Standards of Medical Care, statin therapy may be considered in patients with dyslipidemia associated with insulin resistance or androgen excess. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Rosuvastatin products are separately regulated, and clinical decisions belong with the prescribing clinician.